ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr.

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those ...

Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...

Advanced lab-grown tissues help show how special lung cells develop, shedding light on rare ACDMPV disease and suggesting potential ways to repair damage from viral infections such as COVID-19 ...

Since the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), understanding the mechanisms underlying ...

Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the ...

Only five days after FDA approval of Yutrepia, Liquidia announced its first commercial shipment of the therapy, making prescriptions available to patients at specialty pharmacies. “We have moved with ...

From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Regardless of chronic obstructive pulmonary disease status, finerenone mitigates clinical events and symptoms in patients with HFmrEF or HFpEF.